Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 12
2004 10
2005 7
2006 13
2007 8
2008 10
2009 7
2010 10
2011 13
2012 8
2013 8
2014 7
2015 8
2016 3
2017 14
2018 16
2019 10
2020 9
2021 16
2022 10
2023 11
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
CD8+ T cell-mediated rejection of allogenic human induced pluripotent stem cell-derived cardiomyocyte sheets in human PBMC-transferred NOG MHC double knockout mice.
Matsumoto R, Enzhi Y, Takeda K, Morimoto K, Yogo K, Harada M, Tokushige K, Maehara Y, Hirota S, Kojima Y, Ito M, Sougawa N, Miyagawa S, Sawa Y, Okumura K, Uchida K. Matsumoto R, et al. Among authors: ito m. J Heart Lung Transplant. 2024 Apr 22:S1053-2498(24)01564-X. doi: 10.1016/j.healun.2024.04.003. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 38657776
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Yoshinami T, et al. Among authors: ito m. Int J Clin Oncol. 2024 Apr 23. doi: 10.1007/s10147-024-02504-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38649648
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Ito M, Okumura Y, Nio K, Baba E, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Tsuchihashi K. Ito M, et al. Int J Clin Oncol. 2024 Apr 5. doi: 10.1007/s10147-024-02502-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38578596
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Kimura S, Shigeta K, Tamura S, Uchino K, Kimura T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Miura Y. Kimura S, et al. Among authors: ito m. Int J Clin Oncol. 2024 May;29(5):559-563. doi: 10.1007/s10147-024-02501-7. Epub 2024 Mar 28. Int J Clin Oncol. 2024. PMID: 38538963
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Ozaki Y, et al. Among authors: ito m. Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y. Epub 2024 Mar 25. Int J Clin Oncol. 2024. PMID: 38526621
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Uchino K, Tamura S, Kimura S, Shigeta K, Kimura T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Miura Y. Uchino K, et al. Among authors: ito m. Int J Clin Oncol. 2024 May;29(5):545-550. doi: 10.1007/s10147-024-02491-6. Epub 2024 Mar 22. Int J Clin Oncol. 2024. PMID: 38517658
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Maeda T, Najima Y, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Maeda T, et al. Among authors: ito m. Int J Clin Oncol. 2024 May;29(5):535-544. doi: 10.1007/s10147-023-02465-0. Epub 2024 Mar 18. Int J Clin Oncol. 2024. PMID: 38494578 Free PMC article.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Ichihara E, Ochi N, Makimoto G, Kudo K, Harada D, Ozaki Y, Nishio H, Tsuchihashi K, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Kubo T. Ichihara E, et al. Among authors: ito m. Int J Clin Oncol. 2024 Apr;29(4):355-362. doi: 10.1007/s10147-024-02469-4. Epub 2024 Feb 14. Int J Clin Oncol. 2024. PMID: 38353907
209 results